Autologous Serum Therapy versus Histaglobulin in management of Chronic Idiopathic Urticaria

Comparative Evaluation of Therapeutic Efficacy of Autologous Serum Therapy versus Injection Histaglobulin in Chronic Idiopathic Urticaria: An Open-label Randomized Control Trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063314

Enrollment

Registered

2024-02-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Both agents used for chronic urticaria are supposed to be compared at baseline and then after 12 weeks post completion of therapy in either groups: Comparison of both agents to deduce t

Eligibility

Inclusion criteria

Inclusion criteria: 18 years or above patient willing to give consent and not having any contraindication for the procedure

Exclusion criteria

Exclusion criteria: Active microbial infection, Pregnancy or Lactation, Hypersensitivity to Histaglob injection, Immunosuppressed cases or uncontrolled Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
To compare the therapeutic efficacy of AST and injection Histaglobulin in patients of chronic idiopathic urticaria on the basis of change in Urticaria Activity Score and Dermatology Life Quality Index from baseline after 12 weeks post completion of either modality.Timepoint: At baseline, then at 10 weeks and after 12 weeks from the point of last injection given in either group	—

Secondary

Measure	Time frame
To compare the reduction of antihistamine usage by patient on either of these modalities of therapy for chronic urticaria.Timepoint: One year duration	—

Countries

India

Contacts

Public ContactDr Sushantika

AIIMS, Rishikesh

sushantika1992@gmail.com9026564805

Outcome results